Reproducible quantification of osteoclastic activity: Characterization of a biomimetic calcium phosphate assay
Source abstract
Abstract
Abstract Osteoclasts are responsible for bone and joint destruction in rheumatoid arthritis, periodontitis, and osteoporosis. Animal tusk slice assays are standard for evaluating the effect of therapeutics on these cells. However, in addition to batch‐to‐batch variability inherent to animal tusks, their use is clearly not sustainable. Our objective was to develop and characterize a biomimetic calcium phosphate assay based on the use of phase pure hydroxyapatite coated as a thin film on the surface of culture plates, to facilitate the reproducible quantification of osteoclast resorptive activity. Osteoclasts were formed from RAW 264.7 mouse monocyte cell line using a pro‐resorptive cytokine RANKL (50 ng/mL). No change in substrate appearance was noted after culture with media without cells, or undifferentiated monocytes. Only in the presence of osteoclasts localized areas of calcium phosphate dissolution were observed. The total area resorbed positively correlated with the osteoclast numbers (R2 = 0.99). The resorbed area was significantly increased by the addition of RANKL, and decreased after application of known inhibitors of osteoclast resorptive activity, calcitonin (10 μM), or alendronate (100 μM). Thus, calcium phosphate coated substrates allow reliable monitoring of osteoclast resorptive activity and offer an alternative to animal tusk slice assays. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 903–912, 2014.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Metabolism and Diseases · Bone health and treatments · Orthopaedic implants and arthroplasty
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Dentistry McGill University Montreal, Quebec Canada
Shriners Hospital for Children‐Canada Montreal, Quebec Canada
Institute of Materials Science and Technology, Friedrich Schiller University Jena Germany
Funding
Canadian Institutes of Health Research · Natural Sciences and Engineering Research Council of Canada
References (40)
Show source-provided references
1. 10.1038/nm1096-113210.1038/nm1096-1132 ↗
2. 10.1172/JCI20031606910.1172/JCI200316069 ↗
3. 10.1002/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-910.1002/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9 ↗
4. 10.4049/jimmunol.174.3.169310.4049/jimmunol.174.3.1693 ↗
5. 10.4049/jimmunol.168.10.533310.4049/jimmunol.168.10.5333 ↗
6. 10.1111/j.1600-0757.2010.00347.x10.1111/j.1600-0757.2010.00347.x ↗
7. 10.1097/01.ajp.0000210902.67849.e610.1097/01.ajp.0000210902.67849.e6 ↗
8. 10.1007/BF0031872810.1007/BF00318728 ↗
9. 10.1073/pnas.91.9.356910.1073/pnas.91.9.3569 ↗
10. 10.1096/fasebj.13.10.121910.1096/fasebj.13.10.1219 ↗
11. Pitfalls in pit measurement
12. 10.1210/en.2004-114010.1210/en.2004-1140 ↗
13. 10.1093/hmg/ddn26610.1093/hmg/ddn266 ↗
14. 10.1359/jbmr.1997.12.11.179710.1359/jbmr.1997.12.11.1797 ↗
15. 10.1902/jop.2000.71.4.58610.1902/jop.2000.71.4.586 ↗
16. 10.1007/s00223-002-1051-410.1007/s00223-002-1051-4 ↗
17. 10.1016/j.actbio.2011.09.02010.1016/j.actbio.2011.09.020 ↗
18. 10.1016/j.ab.2010.11.01410.1016/j.ab.2010.11.014 ↗
19. 10.1016/j.actbio.2010.04.01510.1016/j.actbio.2010.04.015 ↗
20. 10.1002/(SICI)1097-4636(19991205)47:3<424::AID-JBM19>3.0.CO;2-010.1002/(SICI)1097-4636(19991205)47:3<424::AID-JBM19>3.0.CO;2-0 ↗
21. 10.1007/s10856-010-4152-z10.1007/s10856-010-4152-z ↗
22. 10.1016/j.biomaterials.2009.04.04410.1016/j.biomaterials.2009.04.044 ↗
23. 10.1002/jbm.a.3033210.1002/jbm.a.30332 ↗
24. 10.1088/1748-6041/7/4/04501210.1088/1748-6041/7/4/045012 ↗
25. 10.1016/j.biomaterials.2008.09.06210.1016/j.biomaterials.2008.09.062 ↗
26. 10.1371/journal.pone.000210410.1371/journal.pone.0002104 ↗
27. 10.1016/j.biomaterials.2008.03.03510.1016/j.biomaterials.2008.03.035 ↗
28. 10.1083/jcb.145.3.52710.1083/jcb.145.3.527 ↗
29. 10.1371/journal.pone.002146210.1371/journal.pone.0021462 ↗
30. 10.1073/pnas.97.4.156610.1073/pnas.97.4.1566 ↗
31. 10.1006/bbrc.1998.978810.1006/bbrc.1998.9788 ↗
32. 10.1172/JCI11445910.1172/JCI114459 ↗
33. 10.1136/jcp.31.12.121210.1136/jcp.31.12.1212 ↗
34. Calcitonin receptor regulation and responsiveness to calcitonin in human osteoclast‐like cells prepared in vitro using receptor activator of nuclear factor‐κB ligand and macrophage colony‐stimulating factor10.1210/endo.141.10.7715 ↗
35. 10.1016/j.biomaterials.2006.04.03010.1016/j.biomaterials.2006.04.030 ↗
36. Structure‐activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen‐containing bisphosphonates
37. Alendronate inhibits invasion of PC‐3 prostate cancer cells by affecting the mevalonate pathway
38. 10.1634/theoncologist.9-90004-310.1634/theoncologist.9-90004-3 ↗
39. 10.1016/8756-3282(85)90051-110.1016/8756-3282(85)90051-1 ↗
40. Selective internalization of the apical plasma membrane and rapid redistribution of lysosomal enzymes and mannose 6 phosphate receptors during osteoclast inactivation by calcitonin10.1242/jcs.97.3.439 ↗